Literature DB >> 2843672

Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.

R J Murray1, D Wang, L S Young, F Wang, M Rowe, E Kieff, A B Rickinson.   

Abstract

Cytotoxic T cells from Epstein-Barr virus (EBV)-immune individuals specifically kill EBV-transformed B cells from HLA class I antigen-matched donors even though the latently infected cells express only a restricted set of virus genes. The virus-induced target antigens recognized by these immune T cells have not been identified. In our experiments, EBV DNA sequences encoding the virus latent gene products Epstein-Barr nuclear antigen (EBNA)1, EBNA 2, and EBNA-LP and the latent membrane protein (LMP) were individually expressed in a virus-negative human B-lymphoma cell line, Louckes. Transfected clones expressing LMP were killed by EBV-specific cytotoxic T-cell preparations from each of three virus-immune donors HLA matched with Louckes through HLA-A2, B44 antigens; control transfectants or clones expressing one of the EBNA proteins were not recognized. Expression of LMP in a second virus-negative B-cell line, BL41, sensitized these cells to EBV-specific cytolysis restricted through the HLA-A11 antigen. To distinguish between the viral protein and an induced human B-cell activation antigen as the target for T-cell recognition, LMP was then expressed in a murine mastocytoma cell line, P815-A11-restricted human T cells. The LMP-expressing P815-A11 transfectants were susceptible to lysis by EBV-specific cytotoxic T cells from three HLA-A11-positive individuals. Both Louckes and P815-A11 cells were also transfected with constructs capable of encoding a truncated form of LMP (Tr-LMP) which lacks the N-terminal 128 amino acids of the full-length protein. Tr-LMP-expressing transfectants were not recognized by the above T-cell preparations. The results suggest that LMP, and, in particular, epitopes derived from the N-terminal region of the protein, provides one of the target antigens for the EBV-induced human cytotoxic T-cell response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843672      PMCID: PMC253518          DOI: 10.1128/JVI.62.10.3747-3755.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

2.  A permanent human cytotoxic T-cell line with high killing capacity against a lymphoblastoid B-cell line shows preference for HLA A, B target antigens and lacks spontaneous cytotoxic activity.

Authors:  H Spits; J E de Vries; C Terhorst
Journal:  Cell Immunol       Date:  1981-04       Impact factor: 4.868

3.  Long-term T-cell-mediated immunity to Epstein-Barr virus.

Authors:  A B Rickinson; D J Moss; L E Wallace; M Rowe; I S Misko; M A Epstein; J H Pope
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

4.  Sequential appearance of Epstein-Barr virus nuclear and lymphocyte-detected membrane antigens in B cell transformation.

Authors:  D J Moss; A B Rickinson; L E Wallace; M A Epstein
Journal:  Nature       Date:  1981-06-25       Impact factor: 49.962

5.  HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus.

Authors:  I S Misko; D J Moss; J H Pope
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

6.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T cells in virus-infected leukocyte cultures.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1979-05-15       Impact factor: 7.396

7.  Epstein-Barr virus RNA VII: size and direction of transcription of virus-specified cytoplasmic RNAs in a transformed cell line.

Authors:  V van Santen; A Cheung; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

8.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

9.  Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro.

Authors:  D J Moss; L E Wallace; A B Rickinson; M A Epstein
Journal:  Eur J Immunol       Date:  1981-09       Impact factor: 5.532

10.  HLA-restricted T-cell recognition of Epstein-Barr virus-infected B cells.

Authors:  A B Rickinson; L E Wallace; M A Epstein
Journal:  Nature       Date:  1980-02-28       Impact factor: 49.962

View more
  25 in total

1.  Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site.

Authors:  J Sample; L Brooks; C Sample; L Young; M Rowe; C Gregory; A Rickinson; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

Review 2.  Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis.

Authors:  D J Moss; I S Misko; T B Sculley; A Apolloni; R Khanna; S R Burrows
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes.

Authors:  C M Rooney; M Brimmell; M Buschle; G Allan; P J Farrell; J L Kolman
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Absence of HLA class I expression by Reed-Sternberg cells.

Authors:  S Poppema; L Visser
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

5.  Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.

Authors:  M Cordier; A Calender; M Billaud; U Zimber; G Rousselet; O Pavlish; J Banchereau; T Tursz; G Bornkamm; G M Lenoir
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

6.  Identification of a glucocorticoid-responsive element in Epstein-Barr virus.

Authors:  S R Kupfer; W C Summers
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Association of Epstein-Barr virus (EBV) with Sjögren's syndrome: differential EBV expression between epithelial cells and lymphocytes in salivary glands.

Authors:  S Wen; N Shimizu; H Yoshiyama; Y Mizugaki; F Shinozaki; K Takada
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

8.  Identification and characterization of a human cytomegalovirus gene coding for a membrane protein that is conserved among human herpesviruses.

Authors:  R Lehner; H Meyer; M Mach
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

Review 9.  Human herpesviruses: a consideration of the latent state.

Authors:  J G Stevens
Journal:  Microbiol Rev       Date:  1989-09

10.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity.

Authors:  D Wang; D Liebowitz; F Wang; C Gregory; A Rickinson; R Larson; T Springer; E Kieff
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.